Omeros (OMER) Liabilities and Shareholders Equity (2010 - 2026)
Omeros (OMER) reported Liabilities and Shareholders Equity of $286.2 million for Q1 2026, up 21.69% on a YoY basis from $235.2 million in Q1 2025, and down 12.12% sequentially from $325.6 million in Q4 2025.
Omeros (OMER) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $286.2 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 21.69% year-over-year to $286.2 million; the trailing twelve-month figure through Mar 2026 stood at $998.1 million (down 15.55% YoY), and the FY2025 full-year result was $325.6 million, up 17.52% from the prior year.
- Liabilities and Shareholders Equity eased to $286.2 million in Q1 2026, from $325.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $591.0 million in Q4 2022 to a low of $185.7 million in Q3 2025.
- A 5-year average of $372.9 million and a median of $356.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity jumped 270.7% in 2022 and tumbled 46.25% in 2025, its largest moves.
- Tracing OMER's Liabilities and Shareholders Equity over 5 years: stood at $591.0 million in 2022, then tumbled by 35.99% to $378.3 million in 2023, then slipped by 26.75% to $277.1 million in 2024, then gained by 17.52% to $325.6 million in 2025, then fell by 12.12% to $286.2 million in 2026.
- Business Quant data shows OMER's Liabilities and Shareholders Equity at $286.2 million in Q1 2026, $325.6 million in Q4 2025, and $185.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | 286.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 286.17 Mn |
| Dec 31, 2025 | 325.63 Mn |
| Sep 30, 2025 | 185.71 Mn |
| Jun 30, 2025 | 200.57 Mn |
| Mar 31, 2025 | 235.16 Mn |
| Dec 31, 2024 | 277.08 Mn |
| Sep 30, 2024 | 313.34 Mn |
| Jun 30, 2024 | 356.31 Mn |
| Mar 31, 2024 | 437.49 Mn |
| Dec 31, 2023 | 378.27 Mn |
| Sep 30, 2023 | 493.07 Mn |
| Jun 30, 2023 | 527.42 Mn |
| Mar 31, 2023 | 560.13 Mn |
| Dec 31, 2022 | 590.97 Mn |
| Sep 30, 2022 | 457.55 Mn |
| Jun 30, 2022 | 345.64 Mn |
| Mar 31, 2022 | 369.26 Mn |
| Dec 31, 2021 | 419.27 Mn |
| Sep 30, 2021 | 123.43 Mn |
| Jun 30, 2021 | 145.39 Mn |